Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Kawin Technology Share-Holding Co., Ltd. (688687.SS)
Beijing, CN
Established in 2008 and based in Beijing, China, Beijing Kawin Technology Share-Holding Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, with a primary emphasis on treatments for liver conditions within the Chinese market. Its key offerings include recombinant human interferon alfa-2b injection and compound glycyrrhizin. Beyond its own product line, the company supplies active pharmaceutical ingredients (APIs) and delivers comprehensive clinical research services for advancing biological products. These services encompass the fermentation and purification of drug substances, drug product formulation, and the creation of analytical methods. Beijing Kawin also offers contract manufacturing solutions. The company's global footprint includes serving customers in countries such as Pakistan, Colombia, the Philippines, Vietnam, Russia, and Cambodia, among others. Furthermore, it maintains strategic partnerships with entities like Legend Capital, Haitong Capital, and Cybernaut.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.22% | -7.44% | -13.77% | -22.83% | -34.16% | -31.62% | -38.37% | -33.90% | -53.70% | -59.43% | -59.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+7.4% ★ Q1'26: -10.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-78.8% Q1'26: -73.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-10.0% Q1'26: -6.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+4.3% ★ Q1'26: +4.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+4.0% ★ Q1'26: +2.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.1% Q1'26: -10.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.01× ★ Q1'26: 11.75× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.16B
est: 1.46B (-20.4%)
|
1.41B
est: 1.44B (-1.9%)
|
1.23B
est: 1.60B (-22.9%)
|
1.32B
est: 1.21B (+9.3%)
|
1.39B
961.64M – 1.81B
+14.8% YoY
|
1.56B
1.29B – 1.83B
+12.5% YoY
|
1.50B
1.24B – 1.76B
-3.7% YoY
|
| EBITDA |
135.13M
est: 210.11M (-35.7%)
|
185.26M
est: 187.11M (-1.0%)
|
220.58M
est: 207.40M (+6.4%)
|
111.02M
est: 156.98M (-29.3%)
|
180.24M
124.97M – 235.51M
+14.8% YoY
|
202.85M
167.91M – 237.79M
+12.5% YoY
|
195.27M
161.63M – 228.91M
-3.7% YoY
|
| EBIT |
98.69M
est: 159.49M (-38.1%)
|
147.20M
est: 139.64M (+5.4%)
|
178.51M
est: 154.79M (+15.3%)
|
56.60M
est: 117.16M (-51.7%)
|
134.52M
93.27M – 175.77M
+14.8% YoY
|
151.40M
125.32M – 177.48M
+12.5% YoY
|
145.74M
120.63M – 170.84M
-3.7% YoY
|
| Net Income |
83.41M
est: 118.92M (-29.9%)
|
116.52M
est: 120.57M (-3.4%)
|
142.37M
est: 147.35M (-3.4%)
|
30.60M
est: 139.44M (-78.1%)
|
163.84M
127.15M – 200.53M
+17.5% YoY
|
185.00M
146.09M – 230.40M
+12.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
853.14M
est: 891.62M (-4.3%)
|
896.32M
est: 916.07M (-2.2%)
|
712.36M
est: 1.02B (-29.8%)
|
654.64M
est: 768.57M (-14.8%)
|
882.45M
611.83M – 1.15B
+14.8% YoY
|
993.16M
822.08M – 1.16B
+12.5% YoY
|
956.05M
791.36M – 1.12B
-3.7% YoY
|
| EPS |
0.49
est: 0.71 (-31.0%)
|
0.70
est: 0.72 (-2.5%)
|
0.85
est: 0.83 (+2.4%)
|
0.18
est: 0.80 (-77.5%)
|
0.94
0.73 – 1.15
+17.5% YoY
|
1.08
0.84 – 1.32
+14.9% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 2/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 2/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chongfei He | Vice President, Secretary to the Board & Chief Financial Officer | — | male |
| Desheng Zhou | President & Chairman of the Board | — | male |
| Hong Juan Liu | Accounting Supervisor | — | — |
| Huan Wang | Executive Vice President & Director | — | female |
| Jian Tang | Vice President | — | male |
| Jifeng Shi | Vice President, Chief Research Officer, Core Technical Personnel & Director | — | male |
| Lu Yang | Deputy GM of Beiyi Protein Drug R&D and Core Technical Personnel | — | male |
| Shan Liu | Head of Antibody Drug Development Department & Core Technical Personnel | — | female |
| Xiang Li | Manager of Information Strategy Research Department & Core Technical Personnel | — | male |
| Xiao Xu | Vice President | — | female |
| Yan Cui | Director of Human Resources Department & Employee Representative Supervisor | — | female |
| Zhan Wang | Chief Human Resources Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688687.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
